Jefferies highlights AstraZeneca Covid-19 vaccine data impact on India | Price, rivals to distribution, know it all
AstraZeneca vaccine will be able to vaccinate only 50% of the population by the end 2022, even if there are no supply/ funding constraints, according to Jefferies. A 70% efficacy with AstraZeneca would further delay the time to bring the Pandemic under control in India. High unmet demand leaves potential for other vaccine plays in India. Remdesivir could also see extended sales for Cipla and Cadila Healthcare.
AstraZeneca has shown 70% efficacy in its vaccine trial data. This implies that the vaccine will provide immunity to only 70% of patients who get immunized: Reuters